The median overall survival with nivolumab and temozolomide chemotherapy was 13.4 (12.6-14.3) and 14.9 (13.3-16.1) months, respectively (hazard ratio =1.31 (1.09-1.58), P = 0.0037), and the median progression free survival with nivolumab and temozolomide chemotherapy was 6.0 (5.7-6.2) and 6.2 (5.9-6.7) months, respectively, in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter (39). This evidence concerns the gene MGMT and glioblastoma.